Thc monitoring of compliance in outpatients using serum drug Icvels suffers from the difficulty of relating conccntrations to changes in dosage. ('lcarancc is independent of dosc for most drugs, and may he predicted using a Baycsian based forecasting program. This paper' dcscribcs how thc apparent clcarancc obtained following a single drug analysis can he compared with the Baycsian population valuc to derive a Compliance Index. In compliant individuals with stable hepatic and renal function this index should remain constant. We evaluated the usefulness of the Compliance Index in general practice with patients prescribed thcophyllinc. Of 54 patients examined on up to five occasions, only 12Y0 werc deemcd to be fully compliant at all times. Compliance improved during the study, but worsened again once regular consultation ceased. Thc results indicatc that such a Compliance Index is a viable method of assessing compliance with the aid of concentration measurements.
Additiotiul kcj. phr-cisc~s: tlicrupcutic drug t?ionitorin,q; B N~Y S '
Tiicwrc~ni; out puticwts Failure to take prescribed medication either at the correct time or in the correct dosage is extremely common, especially in patients prescribed long-term therapy. Estimates of compliance vary between 24-93% depending upon pathology and the method of assessment used.' Compliance may be assessed directly, by measurement of the drug, its metabolites or a marker in serum or urine' or indirectly by observing the therapeutic outcome, physician prediction, patient interview or pill count. Direct measures are preferable.' In situations where the patient's drug intake is unsupervised, improvements in compliance can be achieved by efficient organization of clinics, helpful packaging of medicines, clear instructions and behavioural reinforcement.' The influence of dosing frequency on compliance is controver~ial;~.~ up to 90% of patients make some unintentional errors. 4 Theophylline is widely prescribed and monitoring of serum concentrations has bccn shown to reduce the incidence of adverse reactions.' Compliance with theophylline therapy has been examined by several groups'~' and has been reviewed.' It has been suggested that up to 75% Correspondence: Dr 1 D Watson, Department of Biochemistry, Fazakerley Hospital, Longmoor Lane, Liverpool L9 7AL. UK. of asthmatic childrcn are non-compliant.' Comparison of levels before and during supcrvised intake in hospital indicated that 41%) of 63 patients in a gcneral practice werc deemcd n o n -
The usc of serum thcophylline concentrations to individualize treatment has bccn practised since the 1970s when the relationship between thcophylline pharmacokinetics and pharmacodynamics was established.'."' I' Factors which cause inter-individual kinetic variation include: age, sex, weight,"." I' smoking pattern".'" and disease states such as congestive cardiac failure and cirrhosis." Clearance may also he altered by chronic dosing.2" Assessment of compliance is the reason frequently given for measuring the seriim theophylline concentration. An inadequate dose or dose frequency, rapid clearance or malabsorption are alternative explanations for an inappropriately low theophylline concentration, hence serum concentration measurement is not an objective measurc of compliance. More recently predictive kinetics based on population data have been used to compare the observed scrum concentration with the predicted concentration." The authors concluded that this was a useful method of assessing compliance. We Assessment of theophylline compliance 6 1 preparations used were Phyllocontin (Napp Laboratories, Cambridge, UK), Nuelin SA (Riker, Loughborough, UK) or Uniphyllin (Napp Laboratories).
A full history and examination was carried out prior to the study, particular note being taken of smoking habits and hepatic, cardiac and renal function. The patients were accustomed to measuring their peak flows, before retiring and on rising, and to keep an 'attack' and symptom diary which was reviewed at each consultation. All patients had been told of the need for full compliance with their theophylline therapy which was reinforced on every visit, typically fortnightly.
The computer program employed (OPT)" uses Bayesian statistics, a brief outline of which is given below: have used predicted clearance rather than predicted concentration because it is unaffected by dose changes.
Predictive pharmacokinetics are useful in dosage individualization" '' and have been applied to theophylline.2h." A simple onecompartment model based on population values may be used to describe disposition, and from this model estimates of absorption rate constant. volume of distribution, elimination rate constant and total serum clearance may be obtained. Samples are generally obtained with the patient in steady-state and sufficiently long post-dose for elimination to be the dominant process, so changes in clearance (CI) are the major determinants of serum concentration. We have used a Bayesian prediction program (OPT)" which requires input of variables such as height. weight, smoking history, degree of cardiac Failure and dosage information and allows prediction of the serum concentration and drug clearance (CI,,,,,) for that subpopulation of patients. If the actual drug concentration in the patient is measured the program can refine the estimate of clearance to a predicted clearance for that patient (ClprCd). Cross diEerences between the predicted clearance and the subpopuiation clearance or a previous estimate of predicted clearance in the same patient suggest noncompliance. We define the percentage difference between CI,,,, and CI,,,, as the Compliance Index. This is independent of the dose and should therefore be of more value than comparison of observed and predicted serum concentrations which are dose dependent.
This study was designed to test the usefulness of the Compliance Index and compare it with the indirect assessment of compliance as routinely performed in the general practice surgery.
METHODS
Fifty-four patients, 34 women and 20 men (mode age 52 years, range 17-78 years) with a greater than 20% reversible component to their chronic obstructive airway disease (COAD) were entered into the study. Twenty-two of the patients were smokers. All were attending their general practitioner (CEL) and were receiving steroids by inhalation in addition to their long-standing theophylline therapy; no dose changes had been made for at least six weeks prior to patient entry into the study. To minimize the influence of sampling and absorption on serum levels, samples were drawn prior to the next dose. Theophylline
Bayes' Theorem
Bayes' Theorem is applicable in situations where there is foreknowledge of the probability of an event, which is termed prior probability. When an observation is made this will tend to confirm or refute the prior probability, i.e. it will imply it is now more or less probable than before. This is the posterior probability.
The probability estimate obtained could belong to different populations with varying degrees of probability; if sufficient populations are Considered this would result in a probability distribution whose apex would coincide with the most probable estimate. Assignment of the posterior probability to the most probable estimate is termed the Estimate of Maximum Likelihood.
In Bayesian terms the foregoing can be expressed as: posterior probability is proportional to likelihood multiplied by prior probability.
By combining Bayesian statistics and estimates of maximum likelihood it is possible, using minimal information, to estimate which population has been examined given that there is a previously obtained reference.
Bayesian kinetics
The serum drug concentration a t a given time after a given dose is a function of an individual's pharmacokinetics. There will be analytical and pharmacokinetic variation associated with this estimate of concentration, resulting in a distribution of likely estimates. The kinetic factors determining the drug concentration are complex but simple models are often sufficient for accurate prediction, e.g. a one-compartment open model with first order kinetics is commonly used. In such a model three parameters define the serum concentrations: absorption rate, volume of distribution and clearance. In any individual the average values of the three parameters above for the population to which he/she belongs are the prior probability. and an observation of serum drug concentration will amend the prior probability resulting in a posterior probability and 'individualized' values of thc kinetic parameters. Further observations (up to three) refine the estimate.
An element of individualization can be obtained by the use of co-variates such as age, sex, weight which will in effect result in the use of sub-population parametcrs.
Compliance Index
At the first visit a serum sample was sent to the laboratory for theophylline estimation, along with relevant patient data required for the prediction programme, including theophylline formulation prescribed. The result of the analysis was entered into the program and the predicted apparent clearance (Clpred) was compared with the population clearance (Clpclp) for the subset to which the patient belonged. The Compliance Index was defined as:
~Ipop-C~pred
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OPT assigns a variance to CI of * S O % .
Published values for variance of population CI are 20-50°/~,17~28 and we set banding limits at 25%. The reference clearance (ClpoP in the equation) was the apparent clearance obtained at first observation provided this was within 25% of the population subset CI. If the first predicted clearance was more than 25% different from the population clearance, the population clearance was used as a reference clearance. This approach offers a way of dealing with compliant and noncompliant individuals at the initial visit.
Compliance was deemed acceptable if CI,,,, was within f 2 5 % of CI,,, and patients were considered non-compliant if the difference was greater than + so%, intermediate values were considered partially compliant. Patients with a difference of > -25% were categorized as overcompliant. The aim is to obtain a readily usable estimate of compliance which is applicable in the practical situation of a review in a general practitioner clinic as an adjunct to clinical impression. A dosage recommendation was made if indicated (target range for theophylline 55-110pmol/l). A decision was taken that no changes of greater than 50% of the existing dose (in either direction) would be made, regardless of the prcdiction.
An assessment of compliance in each patient was reported to the general practitioner (GP) with a report which showed the predicted serum concentration vs time curve and was useful in confirming patient compliance histories. The procedure was repeated on up to five patient visits and on each occasion the need for compliance was reinforced. Regular reviews of progress were made between physician and laboratory.
The data collected included the clinician's initial indirect assessment of compliancc, based on history. examination, peak flows and patient diary, and two to five direct estimates by calculation of the Compliance Index. Side effccts were also recorded. as were the dosage changes made.
On completion of the study, the effectiveness of apparent compliance improvements was assessed by thc GP making an unannounced domiciliary visit to 26 of the patients, when a further sample and clinical history were obtained. Compliance assessment was carried out as described above. 
Turnround time
Compliance Index predictions were returned to the G P with the laboratory result, typically within one to three working days.
Analyses
Serum samples were analysed on receipt using the EMIT technique (Syva, Maidenhead, UK). The between-batch imprecision at the mid-point of our target range (80pmol/L) was 5.3% over the period encompassing the study.
Prediction
Prediction was carried out using the Bayesian 
Summary of present treatment:
Concentration measurements (pmol/L):
Comments:
Compliance Index = 1 . Note dose recommendation
FIGURE I . Bayesian kinetics: predicted pharmacokinetic parameters: Compliance Index noted in comment section. (Since the predicted clearance is within & 25% of the population clearance. Compliance Index is unity by definiiion -see text.)
RESULTS
During the study period six patients failed to attend, four withdrew due to illness and one died. Data was collected from 181 patient visits. Figure 1 shows the output for predicted parameters, which was sent to the GP. Figure 2 shows a graphical representation of the predicted concentration versus time plot, also sent to the GP.
Initial assessment of compliance
No patients admitted to being non-compliant at the first visit; at this time they were unaware that blood sampling could detect non-compliance.
Using the Compliance Index with CI,,, obtained from the first sample as the reference (provided that this was within +_ 25% of the C1, , , for the relevant subset) 52% of patients were designated compliant, 15% partially compliant and 33% non-compliant. (These figures excluded those who had no measurable theophylline in their serum (n = 6), since these were deemed clearly non-compliant.)
The imprecision (coefficient of variation; CV) associated with the value obtained for ClPred has been estimated as Compliance behaviour A significant shift from non-compliance was detectable as the trial progressed ( Fig. 3) (chi- Buyesiun kinetics: predicted concentration squared, P < 0.05). There was a significant difference between estimates of compliance using the indirect (GP) and direct (Compliance Index) measures (chi-squared, P < 0.001) (Table 1) .
Compliance and dosing
Classifying a patient as compliant reinforced the acceptability to the physician of the dosage advice given. Changes in Compliance Index for three subjects during the course of the study are shown in Fig. 4 . Subject CB, a smoker, was designated as compliant throughout her clinic attendance, during which time two dosage increments were made from an original dose of 225 mg twice daily to 450 mg in the morning, 225 mg at night and then to 450mg twice daily. This last dose achieved serum theophylline concentrations in the lower half of the target range. Subject JK, a non-smoker, was erratically compliant and no dosage changes were made although two were recommended. Subject TMcG, a non-smoker, was compliant prior to a recommended dose change with which he initially complied, but later became non-compliant due to nausea. He had attained a serum theophylline concentration at the upper end of the target range when changed from 450mg twice daily to 675mg twice daily which was consistently predicted by the program. Even if given 450 mg three times daily the mean predicted steady state maximum concentrations were towards the upper half of the target range. Consistency of prediction was necessary before a dose change was implemented (mode 2 predictions, range 1-4). The amount of drug prescribed was a factor in how rapidly dose changes would be made, low daily doses ( < 500mg/day) study (excluding domiciliary visit) . The number of patients at each observation were: 5 4 . 4 3 , 3 8 , 2 6 and 20, respectively. Non-complian t Consecutive Compliance Indicies in three (n = 14) had a mode of two predictions, high daily doses ( > 500 mg/day)(n = 10) had a mode of three predictions. These were significantly different (chi-squared, P < 0.001).
Domiciliary visit
Results obtained from the specimens taken at the domiciliary visit indicated much lower compliance than had been observed at the last visit to the clinic. Using the Compliance Index, only 3 1 YO were classed as compliant, 3 1 % as partially compliant and 38% as non-compliant. Thirtyfive per cent (i.e. 92% of non-compliers) admitted their non-compliance before the results of the Compliance Index were available.
Overall compliance
Using the G P assessments, only 20% of patients were classed as fully compliant over the course of the study. A further 20% were partially compliant, and the remainder had at least one episode of non-compliance. The Compliance Index showed only 12% as being fully compliant over the whole study, with 59% having at least one period of non-compliance. Partial compliance was maintained at the expense of full compliance, however, since patients judged after three visits to be compliant were not counselled further, part of the increased percentage of non-compliers may be associated with the fact that these were those who required more counselling.
A substantial number of patients were persistently non-compliant and of those whose compliance improved a proportion lost their motivation following the end of the formal study, as shown by the results of the domiciliary visit.
DISCUSSION
Choice of compliance index
Since non-compliance with therapy can range from total abstinence to the missing of a single dose, a sensitive measure of difference between expected and observed results is necessary to ascertain whether the drug is being taken as prescribed.
Direct measures of compliance have been reported to be more reliable and objective than indirect methods. 2 The most commonly used direct method is the serum theophylline concentration, but this will vary with the dose and frequent changes in dosage (or dosing interval) may be prescribed within a period of a year. Seasonal variations may also be a contributing factor.30 Therefore while a low serum concentration may indicate non-compliance (in the absence of malabsorption or rapid clearance) it could simply reflect a low dose, and a level within the target range may still be associated with a degree of non-compliance.
Bayesian forecasting is claimed to be superior to nomograms for dosage predi~tion.~' De Tullio et al. also used kinetic modelling to predict plasma theophylline concentration2' and employed the ratio between observed and predicted concentrations as a measure of compliance. They noted the limitations of this approach as individual variance, assay imprecision and inaccuracy in the calculations.
Provided that adequate data on dose, time from dose to sampling, and morphometric parameters is available, changes in predicted apparent clearance can be used as markers of compliance, and the degree of deviation from the population mean for the subset may be used as an index of compliance. Estimates of the range around the mean population of theophylline clearance vary from 20-50%.'7~28 We defined good compliance as clearance values within 25% of the population mean with increases over this signifying decreasing compliance. Since ClPrcd is independent of dosage, the degree of deviation may be scored consistently. We are unaware of any previous use of this approach for compliance assessment.
A calculation of Compliance Index from a further investigation either confirms the initial classification or allows a revised estimate of compliance. In practice, this was found to give a satisfactory classification in all but one patient, and in an acceptable turnround time. This last point is important as the Compliance Index is intended as a practical adjunct to the routine challenge of compliance in out-patients-if assays were available at the GP's surgery it would also be possible to use such a program in the same location provided the system was operated by an individual with knowledge of pharmacokinetics.
The GP-assessed compliance ratings (indirect) were different from those obtained using the Compliance Index (direct), which highlights the difficulties inherent in the assessment of noncompliance, although the same trends were observed. Compliance improved between the first and subsequent visits as some patients realized that their statements could be checked. The reinforcement, which has been shown to improve compliance,2 occasionally led to overcompliance; this has been noted before,8 and is potentially dangerous with a drug such as theophylline with a low therapeutic index. Further monitoring can help avoid this, as well as ensuring continued r e i n f~r c e m e n t~~ which seemed to be enhanced by showing the patients the graphical display of the serum concentration/time curve. However, the domiciliary visit indicated that once the reinforcements were removed, overall compliance decreased to the original level. Some patients, who admitted that they had relapsed on cessation of the study made an unprompted admission to taking the tablets for three days before coming to a scheduled visit. As this is the length of time required to achieve steady state, we may have taught the patients some pharmacokinetics by showing them the predicted serum concentration vs time curve. No current technique can detect such manipulative behaviour. If the Compliance Index were to be applied to a drug which had a metabolite with a long half-life such conduct could be detected.
This study suggest that only a small minority of patients (1 2%) prescribed theophylline are fully compliant at all times. This compares with the findings of G r~c n b e r g ,~ although Taylor' found 41 YO of his patients were non-compliant.
Some of our patients were consistently noncompliant whereas others showed only one episode out of three to five occasions. The detection of persistent non-compliance is valuable since it is pointless either prescribing a drug or checking its concentration with a view to making a dose change in such cases.
Close interaction between laboratory and the GP and above average efforts on communication with the patients on the part of the G P allowed the achievement of short term improvement in this study but is unlikely to be sustained in many cases. However, where such efforts are deemed most appropriate, the use of a clearance-based compliance index can give an objective measurement required for the classification of compliance in the outpatient population and is useful in compliance reinforcement provided that this is continued.
